3rd Annual Hematologic Malignancies Symposium

 

3rd Annual Hematologic Malignancies Symposium
C

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Therapy Strategies and Outcomes

By 3rd Annual Hematologic Malignancies Symposium FEATURING Courtney D. DiNardo
By 3rd Annual Hematologic Malignancies Symposium FEATURING Courtney D. DiNardo
235 views
April 8, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
Videos
26:33

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Ben…

3rd Annual Hematologic Malignancies Symposium

A. Perl

145 views
07:34

2021 Updates on FLT3m R/R AML: What Is the Current Standard of Care?…

3rd Annual Hematologic Malignancies Symposium

A. Perl

218 views
15:35

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

3rd Annual Hematologic Malignancies Symposium

G. Roboz

127 views
22:10

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Th…

3rd Annual Hematologic Malignancies Symposium

C. DiNardo

235 views
26:23

HMA Resistance & Treatment After HMT Failure in MDS: Aza vs. CCR, In…

3rd Annual Hematologic Malignancies Symposium

H. Carraway

131 views
15:41

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Out…

3rd Annual Hematologic Malignancies Symposium

A. Wei

421 views